Results 51 to 60 of about 16,499 (206)
ABSTRACT Multiple myeloma (MM) is an incurable malignancy of terminally‐differentiated plasma cells that represents a major clinical challenge despite unprecedented therapeutic advances, particularly for patients with cytogenetically‐defined high‐risk MM (HR‐MM).
Niamh McAuley +10 more
wiley +1 more source
ABSTRACT Light chain monoclonal gammopathy of undetermined significance (LC‐MGUS) is defined by an abnormal serum free light chain ratio and elevated involved light chain in the absence of a detectable immunoglobulin heavy chain on immunofixation and of end‐organ damage attributable to a plasma cell disorder.
Sigurður Yngvi Kristinsson +2 more
wiley +1 more source
SGLT‐2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma
ABSTRACT Aims We aimed to investigate drug response of sodium‐glucose transport protein‐2 inhibitors (SGLT2i) in multiple myeloma (MM), as SGLT2i have potential favorable effects on conditions related to MM. Methods We conducted a pharmacoepidemiologic study with a US nationwide health insurance claim data using Cox models to investigate the ...
Enze Liu +6 more
wiley +1 more source
Unusual Manifestations of Monoclonal Gammopathy: I. Ocular Disease
Essential monoclonal gammopathy is usually an asymptomatic condition, the characteristics of which have been defined over approximately 70 years of study.
Sophia R. Balderman +1 more
doaj +1 more source
ABSTRACT Objectives To determine the prevalence and prognostic significance of the SKY92 gene‐expression signature, evaluate minimal/measurable residual disease (MRD), and identify molecular drivers of high‐risk disease in transplant‐eligible newly diagnosed multiple myeloma (TE‐NDMM) patients in the Republic of Ireland.
Roisin M. McAvera +24 more
wiley +1 more source
The Myeloma Risk Variant of TNFRSF13B Shows Reduced NF‐κB Signalling Activity in HEK293 Cells
ABSTRACT A single nucleotide variant rs34562254 in TNFRSF13B, which encodes TACI (transmembrane activator and CAML interactor), is associated with an increased risk of myeloma and MGUS. This variant encodes a proline to leucine substitution at residue 251 in the long isoform (P251L) and residue 205 in the short isoform (P205L) of TACI.
Richard Muyan Chen +5 more
wiley +1 more source
Discrete Papular Lichen Myxedematosus and Scleromyxedema with Hypothyroidism: A Report of Two Cases
Scleromyxedema and lichen myxedematosus (LM) are rare disorders that fall along the spectrum of primary cutaneous mucinoses. Scleromyxedema is a systemic form that classically presents with generalized waxy papules, sclerodermoid eruption, and monoclonal
Adele Shenoy +3 more
doaj +1 more source
Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma
IMiDs are pivotal in the treatment of multiple myeloma. Mechanisms of resistance comprise cell intrinsic and extrinsic pathways, involving tumour microenvironment, immune cell dysfunction, CRBN‐dependent and independent genetic drivers and epigenetic changes.
Maria‐Cynthia Fuentes‐Lacouture +3 more
wiley +1 more source
Clinical Diversity and Treatment Outcomes in IgM Monoclonal Gammopathy Associated with Cold Agglutinin Disease and Cryoglobulinemia: A Single Center Study [PDF]
Background: Cold agglutinin disease (CAD) and cryoglobulinemia are rare immune-mediated complications of IgM monoclonal gammopathies, such as Waldenström macroglobulinemia (WM) and monoclonal gammopathy of undetermined significance (MGUS).
Larisa ZIDARU +5 more
doaj +1 more source
The clinical effects of selective IL‐23 inhibition in refractory pyoderma gangrenosum, highlighting progressive ulcer healing, reduction in inflammation and pain, and steroid‐sparing effect, supporting the role of the IL‐23/Th17 axis as a therapeutic target.
Luca Bettolini +25 more
wiley +1 more source

